GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, ‘MAV/06’

2026-03-11 - 06:40

Demonstrates effectiveness comparable to the global standard Oka strain vaccine YONGIN, South Korea, March 11, 2026 /PRNewswire/ — GC Biopharma(006280.KS), a leading provider of biopharmaceutical products in South Korea, announced today that a review paper comprehensively analyzing the safety and immunogenicity of its independently developed varicella vaccine strain, ‘MAV/06’, has been published in the ‘Human